Recognition of double-stranded RNA by proteins and small molecules.

Molecular recognition of double-stranded RNA (dsRNA) is a key event for numerous biological pathways including the trafficking, editing, and maturation of cellular RNA, the interferon antiviral response, and RNA interference. Over the past several years, our laboratory has studied proteins and small molecules that bind dsRNA with the goal of understanding and controlling the binding selectivity. In this review, we discuss members of the dsRBM class of proteins that bind dsRNA. The dsRBM is an approximately 70 amino acid sequence motif found in a variety of dsRNA-binding proteins. Recent results have led to a new appreciation of the ability of these proteins to bind selectivity to certain sites on dsRNA. This property is discussed in light of the RNA selectivity observed in the function of two proteins that contain dsRBMs, the RNA-dependent protein kinase (PKR) and an adenosine deaminase that acts on dsRNA (ADAR2). In addition, we introduce peptide-acridine conjugates (PACs), small molecules designed to control dsRBM-RNA interactions. These intercalating molecules bear variable peptide appendages at opposite edges of an acridine heterocycle. This design imparts the potential to exploit differences in groove characteristics and/or base-pair dynamics at binding sites to achieve selective binding.

[1]  A. Baranger,et al.  Inhibition of the U1A-RNA complex by an aminoacridine derivative. , 2002, Bioorganic & medicinal chemistry letters.

[2]  C. Carlson,et al.  Selection of Small‐Molecule Mediators of the RNA Regulation of PKR, the RNA‐Dependent Protein Kinase , 2002, Chembiochem : a European journal of chemical biology.

[3]  P. Beal,et al.  Controlling protein activity with ligand-regulated RNA aptamers. , 2002, Chemistry & biology.

[4]  R. Griffey,et al.  SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. , 2002, Journal of medicinal chemistry.

[5]  P. Beal,et al.  The binding site of the RNA‐dependent protein kinase (PKR) on EBER1 RNA from Epstein–Barr virus , 2002, EMBO reports.

[6]  C. Carlson,et al.  Point of attachment and sequence of immobilized peptide-acridine conjugates control affinity for nucleic acids. , 2002, Journal of the American Chemical Society.

[7]  P. Beal,et al.  Identification of binding sites for both dsRBMs of PKR on kinase-activating and kinase-inhibiting RNA ligands. , 2002, Biochemistry.

[8]  Brenda L Bass,et al.  RNA editing by adenosine deaminases that act on RNA. , 2002, Annual review of biochemistry.

[9]  J. Feigon,et al.  A novel family of RNA tetraloop structure forms the recognition site for Saccharomyces cerevisiae RNase III , 2001, The EMBO journal.

[10]  E. Evguenieva-Hackenberg,et al.  Both N‐terminal catalytic and C‐terminal RNA binding domain contribute to substrate specificity and cleavage site selection of RNase III , 2001, FEBS letters.

[11]  A. Nicholson,et al.  Intrinsic double-stranded-RNA processing activity of Escherichia coli ribonuclease III lacking the dsRNA-binding domain. , 2001, Biochemistry.

[12]  P. Beal,et al.  Conformational changes that occur during an RNA-editing adenosine deamination reaction. , 2001, The Journal of biological chemistry.

[13]  G. Varani,et al.  Targeting RNA with small-molecule drugs: therapeutic promise and chemical challenges. , 2001, Accounts of chemical research.

[14]  A. Cheng,et al.  Design of RNA-binding proteins and ligands. , 2001, Current opinion in structural biology.

[15]  D. Turner,et al.  Recognition elements for 5' exon substrate binding to the Candida albicans group I intron. , 2001, Biochemistry.

[16]  W. Wilson,et al.  Inhibition of the HIV-1 rev-RRE complex formation by unfused aromatic cations. , 2001, Bioorganic & medicinal chemistry.

[17]  S. Sorey,et al.  Peptide bis-intercalator binds DNA via threading mode with sequence specific contacts in the major groove. , 2001, Chemistry & biology.

[18]  P. Beal,et al.  Selective binding by the RNA binding domain of PKR revealed by affinity cleavage. , 2001, Biochemistry.

[19]  A. Caudy,et al.  Role for a bidentate ribonuclease in the initiation step of RNA interference , 2001 .

[20]  K. A. Lehmann,et al.  Double-stranded RNA adenosine deaminases ADAR1 and ADAR2 have overlapping specificities. , 2000, Biochemistry.

[21]  S. Nanduri,et al.  A dynamically tuned double‐stranded RNA binding mechanism for the activation of antiviral kinase PKR , 2000, The EMBO journal.

[22]  C. Carlson,et al.  Solid-phase synthesis of acridine-based threading intercalator peptides. , 2000, Bioorganic & medicinal chemistry letters.

[23]  T. Giordano,et al.  RNA as a drug target: methods for biophysical characterization and screening. , 2000, Trends in biotechnology.

[24]  M. Ares,et al.  Substrate recognition by a eukaryotic RNase III: the double-stranded RNA-binding domain of Rnt1p selectively binds RNA containing a 5'-AGNN-3' tetraloop. , 2000, RNA.

[25]  D. Feldmeyer,et al.  Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2 , 2000, Nature.

[26]  T. Hermann,et al.  Strategies for the Design of Drugs Targeting RNA and RNA-Protein Complexes. , 2000, Angewandte Chemie.

[27]  B. Bass,et al.  In vitro analysis of the binding of ADAR2 to the pre-mRNA encoding the GluR-B R/G site. , 2000, RNA.

[28]  C. Carlson,et al.  Solid-phase synthesis of acridine-peptide conjugates and their analysis by tandem mass spectrometry. , 2000, Organic letters.

[29]  Chi‐Huey Wong,et al.  Design of Small Molecules That Recognize RNA: Development of Aminoglycosides as Potential Antitumor Agents That Target Oncogenic RNA Sequences , 2000 .

[30]  Gabriele Varani,et al.  RNA recognition by a Staufen double‐stranded RNA‐binding domain , 2000, The EMBO journal.

[31]  A. Litovchick,et al.  Aminoglycoside-arginine conjugates that bind TAR RNA: synthesis, characterization, and antiviral activity. , 2000, Biochemistry.

[32]  D. Patel,et al.  Adaptive recognition by nucleic acid aptamers. , 2000, Science.

[33]  D J Segal,et al.  Design of novel sequence-specific DNA-binding proteins. , 2000, Current opinion in chemical biology.

[34]  Sarah R. Kirk,et al.  Neomycin−Acridine Conjugate: A Potent Inhibitor of Rev-RRE Binding , 2000 .

[35]  R. Schroeder,et al.  Modulation of RNA function by aminoglycoside antibiotics , 2000, The EMBO journal.

[36]  D E Wemmer,et al.  Designed sequence-specific minor groove ligands. , 2000, Annual review of biophysics and biomolecular structure.

[37]  W D Wilson,et al.  Targeting RNA with small molecules. , 2000, Current medicinal chemistry.

[38]  D. Patel,et al.  Stitching together RNA tertiary architectures. , 1999, Journal of molecular biology.

[39]  W. C. Still,et al.  Inhibition of gene expression in human cells through small molecule-RNA interactions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Williams,et al.  PKR; a sentinel kinase for cellular stress , 1999, Oncogene.

[41]  I. Tinoco,et al.  How RNA folds. , 1999, Journal of molecular biology.

[42]  J. Lehn,et al.  Threading bis-intercalation of a macrocyclic bisacridine at abasic sites in DNA: nuclear magnetic resonance and molecular modeling study. , 1999, Biochemistry.

[43]  C. Bailly,et al.  Synthesis and antiviral activity of ethidium-arginine conjugates directed against the TAR RNA of HIV-1. , 1999, Journal of medicinal chemistry.

[44]  K. A. Lehmann,et al.  The importance of internal loops within RNA substrates of ADAR1. , 1999, Journal of molecular biology.

[45]  Batey,et al.  Tertiary Motifs in RNA Structure and Folding. , 1999, Angewandte Chemie.

[46]  M Afshar,et al.  Structure-based and combinatorial search for new RNA-binding drugs. , 1999, Current opinion in biotechnology.

[47]  P. Moore,et al.  Structural motifs in RNA. , 1999, Annual review of biochemistry.

[48]  S C Schultz,et al.  Molecular basis of double‐stranded RNA‐protein interactions: structure of a dsRNA‐binding domain complexed with dsRNA , 1998, The EMBO journal.

[49]  Y. Tor,et al.  Designing Novel RNA Binders , 1998 .

[50]  A. W. Czarnik,et al.  Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules. , 1998, Biochemistry.

[51]  B. Williams,et al.  Structure of the double‐stranded RNA‐binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA‐mediated activation , 1998, The EMBO journal.

[52]  R. Rando,et al.  A high-throughput fluorescence screen to monitor the specific binding of antagonists to RNA targets. , 1998, Analytical biochemistry.

[53]  T. Klimkait,et al.  A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. , 1998, Biochemistry.

[54]  T. Hermann,et al.  Saccharide–RNA recognition , 1998, Biopolymers.

[55]  Christine S. Chow,et al.  A Structural Basis for RNA−Ligand Interactions , 1997 .

[56]  A. W. Czarnik,et al.  Discovery of selective, small-molecule inhibitors of RNA complexes--II. Self-splicing group I intron ribozyme. , 1997, Bioorganic & medicinal chemistry.

[57]  R. Emeson,et al.  Regulation of serotonin-2C receptor G-protein coupling by RNA editing , 1997, Nature.

[58]  D. Patel,et al.  Imino proton exchange and base-pair kinetics in the AMP-RNA aptamer complex. , 1997, Journal of molecular biology.

[59]  Kit S. Lam,et al.  The “One-Bead-One-Compound” Combinatorial Library Method , 1997 .

[60]  W. Keller,et al.  Purification of Human Double-stranded RNA-specific Editase 1 (hRED1) Involved in Editing of Brain Glutamate Receptor B Pre-mRNA* , 1997, The Journal of Biological Chemistry.

[61]  Inhibition of self-splicing group I intron RNA: high-throughput screening assays. , 1996, Nucleic acids research.

[62]  W. Wilson,et al.  Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives. , 1996, Biochemistry.

[63]  C. de Haro,et al.  The eIF‐2α kinases and the control of protein synthesis 1 , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  T. Cech,et al.  Minor-groove recognition of double-stranded RNA by the double-stranded RNA-binding domain from the RNA-activated protein kinase PKR. , 1996, Biochemistry.

[65]  C. Bailly,et al.  The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism. , 1996, Nucleic acids research.

[66]  P. Seeburg,et al.  A mammalian RNA editing enzyme , 1996, Nature.

[67]  Shiyong Wu,et al.  Double-stranded (ds) RNA Binding and Not Dimerization Correlates with the Activation of the dsRNA-dependent Protein Kinase (PKR) (*) , 1996, The Journal of Biological Chemistry.

[68]  B. Williams,et al.  The interferon-inducible double-stranded RNA-activated protein kinase self-associates in vitro and in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[69]  A. Murzin,et al.  NMR solution structure of a dsRNA binding domain from Drosophila staufen protein reveals homology to the N‐terminal domain of ribosomal protein S5. , 1995, The EMBO journal.

[70]  T. Gibson,et al.  Structure of the dsRNA binding domain of E. coli RNase III. , 1995, The EMBO journal.

[71]  H. Noller,et al.  Directed hydroxyl radical probing of 16S rRNA using Fe(II) tethered to ribosomal protein S4. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[72]  T Kuner,et al.  Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. , 1994, Science.

[73]  G. Zon,et al.  Bulged‐Base Nucleic Acids as Potential Targets for Antiviral Drug Action , 1994 .

[74]  L. Strekowski,,et al.  The interaction of substituted 2‐phenylquinoline intercalates with poly(A) · poly(U): Classical and threading intercalation modes with RNA , 1994, Biopolymers.

[75]  C. Bailly,et al.  Molecular Pharmacology of Intercalator-Groove Binder Hybrid Molecules , 1994 .

[76]  G. Lemay,et al.  Correlation between the presence of a self-splicing intron in the 25S rDNA of C.albicans and strains susceptibility to 5-fluorocytosine. , 1993, Nucleic acids research.

[77]  W D Wilson,et al.  The search for structure-specific nucleic acid-interactive drugs: effects of compound structure on RNA versus DNA interaction strength. , 1993, Biochemistry.

[78]  M. Clemens,et al.  Expression of genes for the Epstein-Barr virus small RNAs EBER-1 and EBER-2 in Daudi Burkitt's lymphoma cells: effects of interferon treatment. , 1992, The Journal of general virology.

[79]  M. Mathews,et al.  Interactions between double-stranded RNA regulators and the protein kinase DAI , 1992, Molecular and cellular biology.

[80]  H. Noller,et al.  Hydroxyl radical cleavage of tRNA in the ribosomal P site. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[81]  W. Denny,et al.  Sequence specificity of the binding of 9-aminoacridine- and amsacrine-4-carboxamides to DNA studied by DNase I footprinting. , 1992, Biochemistry.

[82]  G. Zon,et al.  An ethidium analogue that binds with high specificity to a base-bulged duplex from the TAR RNA region of the HIV-I genome. , 1992, Journal of medicinal chemistry.

[83]  T. Cech,et al.  Visualizing the higher order folding of a catalytic RNA molecule. , 1991, Science.

[84]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[85]  W. Denny,et al.  Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix. , 1990, Journal of medicinal chemistry.

[86]  G. A. van der Marel,et al.  Antitumor drug nogalamycin binds DNA in both grooves simultaneously: molecular structure of nogalamycin-DNA complex. , 1989, Biochemistry.

[87]  G. Zon,et al.  2D NMR investigation of the binding of the anticancer drug actinomycin D to duplexed dATGCGCAT: conformational features of the unique 2:1 adduct. , 1988, Biochemistry.

[88]  R. L. Jones,et al.  1H and 31P NMR investigations of actinomycin D binding selectivity with oligodeoxyribonucleotides containing multiple adjacent d(GC) sites. , 1988, Biochemistry.

[89]  A. Hovanessian,et al.  Autophosphorylation of the protein kinase dependent on double-stranded RNA. , 1987, The Journal of biological chemistry.

[90]  H. Noller,et al.  Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. , 1987, Biochimie.

[91]  C. Samuel,et al.  Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2α kinase , 1986, Cell.

[92]  W. Denny,et al.  Kinetic and equilibrium studies of the interaction of amsacrine and anilino ring-substituted analogues with DNA. , 1986, Cancer research.

[93]  P. Schultz,et al.  Design synthesis of a sequence-specific DNA cleaving molecule. (Distamycin-EDTA)iron(II) , 1982 .

[94]  C. Meares,et al.  Bledta II: Synthesis of a new tumor-visualizing derivative of CO(III)-bleomycin , 1981 .

[95]  R. L. Jones,et al.  Intercalating drugs: DNA binding and molecular pharmacology. , 1981, Advances in pharmacology and chemotherapy.

[96]  M. Sundaralingam,et al.  X-ray-structure of a cytidylyl-3',5'-adenosine-proflavine complex: a self-paired parallel-chain double helical dimer with an intercalated acridine dye. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[97]  H. M. Sobell,et al.  Visualization of drug-nucleic acid interactions at atomic resolution. IV. Structure of an aminoacridine--dinucleoside monophosphate crystalline complex, 9-aminoacridine--5-iodocytidylyl (3'--5') guanosine. , 1979, Journal of molecular biology.

[98]  H. M. Sobell,et al.  Mutagen-nucleic acid intercalative binding: structure of a 9-aminoacridine: 5-iodocytidylyl(3'-5')guanosine crystalline complex. , 1977, Proceedings of the National Academy of Sciences of the United States of America.